7 ms·
At $2.1M, Novartis gene therapy will be world’s most expensive drug
- avocado4 7y agoDo payers in other countries agree to cover 2.1M bill or is it only the US?
- tzakrajs 7y agowaits for generic treatment to surface for 1/10000 of the price in another market
- jtmcmc 7y agothis is not just synthesizing a chemical - this is using an engineered virus to deliver a newly functional gene. There is a reality here that these therapies are really fucking expensive to produce. If we want them to be cheap or free their discovery needs to be subsidized and funded in a non-profit driven manner
- bilbo0s 7y agoActually, tzakrajs is correct. These therapies are just like any other medication as far as their discovery and production are concerned. It requires enormous amounts of resources to discover them. The problem is that once you know the process for an effective therapy, it's relatively easy. So it's critical that access to any information regarding the process used to produce the therapies be as restricted as humanly possible. This is not because drug companies are dastardly profit mongers. (Although that is certainly part of it.) But it's more because we have to fund the research that found that process somehow. People laud places like Cuba because their health care is head and shoulders above the rest of Latin America. (Above even the US in some cases.) But here's the thing, the Cubans simply take all of the research that everyone has done and give it away for free. I understand. Their duty is to their people, not Pfizer. I get that. Here's the thing is though, if everyone does that then the research funding dries up, and the rate of discovery slows. (And yes, I understand that Cuba does its own research and contributes drugs to the global knowledge base as well. Drugs for Hep being a notable example.) But the balance of value is in the drugs researched and discovered by everyone in the world, not just the drugs researched and discovered in Cuba. So what happens when the rest of the world slows down? Well, Cuba gets less overall value too. That, eventually, would hurt the Cuban people just as much as it hurts everyone else. It's relatively easy to take any therapy and use it on your own if you are a state level actor. As someone who had to do business in the health care sector for a long time, I can tell you that with authority. If the Cubans, for example, want to use this badly enough, they will. No amount of complexity will confound Cuban researchers. That's just life. At the same time, it's a very destructive practice under the present circumstances that drug research finds itself in. A more responsible approach would be some sort of global conventions on how to proceed if we want such a system.
- jedberg 7y ago> if everyone does that then the research funding dries up, and the rate of discovery slows. Does it? Or do we go back to the system where universities use government money to do drug research with no profit motive?
- candiodari 7y agoWell it took $8.7 billion to build this drug (granted, most of that was for any viral genetic treatment, and so probably can be amortized in the future. I would point out that that doesn't change that that money was required to get to this treatment). How long until government university research amasses that kind of money ? We all know the answer: more than a century. And now you might say "yes, but half the research was done at universities". That's true, probably more than half, but a significant portion of that was still paid by Novartis. Furthermore Novartis helps professors coordinate, pays for conferences, ... Novartis profit margin is about 20%. In their best years it was 30%. So even in a communist system, this drug would only be 20%-30% cheaper, and take another century before it became available. That would bring it from 1.2 million to, let's round off and say a million. Would that solve your problem with this drug ?
- jedberg 7y agoI never actually said I had a problem with this drug or the price. (I do, but I never said that) Imagine we live in a world where all drug research must be given away freely. Chances are private companies would no longer do the research, since any of their competitors could pick up the research and make it. In which case almost all funding for drug research would revert to universities and drug companies would simply be manufacturers, and would have to compete on manufacturing efficiency. Now, we know that the 8 billion came from somewhere in our economy, so at this point it would be an academic exercise to figure out how to extract that from the economy and transfer it to universities to do the research. What I'm saying is that we need to remove the profit motive in health care, because there is no elasticity in the market. People will pay infinity to keep living. There is no price point where someone says, "that's too much" when it comes to health care, so the market doesn't operate like any other.
- deleted 7y ago[deleted]
- deleted 7y ago[deleted]
- tareqak 7y agoPayers in other countries can use their countries' negotiating power to negotiate with Novartis. The United States is definitely capable of doing the same in theory.
- arkades 7y agoNo, it’s not. Medicare is legally restricted from negotiating drug prices. Yes, that’s a ridiculous law. Edit: to clarify, Medicare does not only cover seniors. Other important groups include those with end-stage renal disease and those with significant disabilities. Those often also receive Medicaid, and are known in industry jargon as “dual-eligible.” Medicare becomes their primary payor, with Medicaid picking up the balance of what Medicare won’t cover. Both programs are ultimately overseen by CMS (center for Medicare and Medicaid services). Pay negotiations for Medicaid occur on a state level, but a huge chunk of the tab is picked up federally, so they tend to weigh in. Newborns with SMA will almost certainly be initially covered by parental private insurance (pre-dx), and transition to dual coverage afterwards. Please note that there are a combination of gene therapies under discussion, only one of which will be given once at birth- the rest will entail ongoing costs that will be borne by Medicare and Medicaid.
- tareqak 7y agoThanks for that 'arkades: I'll update my comment to add "in theory".
- phkahler 7y agoI dont think any insurance company should be able to negotiate prices.
- tareqak 7y agoMight I ask why not? On a personal level, I don't like negotiating myself e.g. I don't like stores that have posted prices. On a macro level, negotiating prices is how large transactions clear such that the buyer and seller get something closest to what they want (hopefully). I do think sane ceilings and floors ceilings for prices have a place in certain situations, but I wouldn't be the best person to characterize what this sanity would be.
- pstrateman 7y agoSomething like this is expensive because... it's actually expensive to do. Typically that means single payer systems simply will refuse to pay for it at all. i.e. this medication will not be available anywhere except the US
- pkaye 7y agoEven within the US it will out of reach to most people even with insurance.
- buildzr 7y agoIs this actually going to be available anywhere but the US? Expensive, rare treatments like this often aren't paid out in socialized systems.
- s1artibartfast 7y agoI expect that the countries covering Spinraza will also cover the new Novartis treatment as it will cut costs. https://www.treatsma.uk/treatments/spinraza/spinraza-access-by-country/ https://www.treatsma.uk/treatments/spinraza/spinraza-access-...
- gruez 7y ago> Novartis is likely to face backlash from critics who believe charging millions of dollars for any medicine — no matter how effective — renders it unaffordable for a healthcare system already under financial stress. If the alternative is no cure at all, what's the issue? I guess you could argue that some governmental organization could be doing it so you can save money by not having to pay out profits, but I doubt voters would support tax hikes to help the 0.001% (or whatever) of the population that has this disease. >There’s also competition. Spinraza, approved in late 2016 and sold by Biogen, has already been used to successfully treat thousands of patients with severe and milder forms of SMA. The drug requires regular spinal infusions costing $750,000 in the first year and $375,000 annually thereafter, for life. $2.1M vs $23.2M (assuming 60 years of life). Seems like a bargin compared to Spinraza.
- mises 7y agoIt's also important to note that advanced drugs for rare illnesses are expensive for a reason: high development costs and a very small market. Costs must amortized over a very few. There also aren't really any economies of scale, because each treatment is unique. Socialized medicine won't cover something like this; the option is a very high price in America or nothing at all.
- omegaworks 7y ago> the option is a very high price in America or nothing at all. False dichotomy. We have robust public and private medical research universities.
- mises 7y ago> We have robust public and private medical research universities. We have a few that give treatment for some things. That does not mean everyone can get treatment; they are not just free hospitals.
- ChrisLomont 7y agoNone of which will pay the billions in R&D and testing required to bring a drug like this to market. Which drugs on this scale were brought to market by these universities?
- hombre_fatal 7y agoThe final quote raises the interesting question: > Peter Bach, director for the center for health policy and outcomes at Memorial Sloan Kettering Cancer Center, is troubled by Zolgensma’s price and believes ICER’s updated cost-effectiveness analysis takes too many liberties. > “You can look at this in either of two ways. It’s an amazing treatment and only a few kids will need it so a million here and million there is not worth more than shoulder shrug,” he said. “Or we have a big problem. Biopharma has been entirely redirected to rare diseases because the market will tolerate any price and the FDA will require pretty minimal data.”
- ThrowawayIP 7y agoThat quote just states that some corporate board rooms have found a local maximum in the profit vs (time to market & R&D costs). Pharma companies do not operate by any moral mandate but are only seeking profit.
- adonovan 7y agoWhy are gene therapies so expensive? Is it simply the need to recoup high R&D costs across a smaller "market" of patients with rare diseases? Or is the marginal per-patient cost actually higher than a regular pharmaceutical?
- return1 7y agoi think the article says it s the former. engineering a virus is not that expensive
- deleted 7y ago[deleted]
- toufka 7y agoThese new gene-/immuno-therapies tend to be: 1) much more sophisticated/cutting edge in terms of R&D, 2) the R&D is all of a new kind, so there has been little prior amortization of resources from prior successes. 3) _curative_, so from a purely market perspective a XX% discount on a [cost/year * lifetime] relative to a small-molecule drug that needs to be taken regularly, forever, is in these very high ranges, and still economically appealing from a cold hard actuarial perspective. The high prices also attract advanced technology development in the area, and I think society wants & demands that rapid technological development of these powerful tools. Imagine trying to pay competitive salaries to a large number of sophisticated genetic engineers and all of their tools and equipment, when there are literally only a five or six products on the market with which to support their efforts. It is still very unclear how we as a society should be paying for that development. And placing that burden on (those) individuals seems unreasonable.
- aaavl2821 7y agoAvexis, the company that developed this drug before Novartis bought it, spent ~$700M to get it approved. The drug will treat a few hundred patients per year. So they have to charge a high price zolgensma is the second gene therapy ever approved in the US. The technical risks are very high and making them at scale at a high level of quality required rare and expensive expertisr
- codeulike 7y agoJust an FYI - The R+D and govt approval process is expensive. The actual treatments are - I'd wager - relatively easy to produce. So this Novartis treatment is delivering DNA fragments via AAV. Its not attempting CRISPR or anything like that, its just gets extra copies of the unmutated gene into the nuclei so the right proteins can get made. I think they call that upregulation. So its basically AAV plus DNA fragments. So for example you can buy engineered AAV viruses online. They sell this stuff for research. Looks like its about $350 a pop https://www.addgene.org/viral-service/aav-prep/ https://www.addgene.org/viral-service/aav-prep/ Novartis aren't using CRISPR here but as another example these guys sell CRISPR for your research experiments: https://www.addgene.org/crispr/guide/ https://www.addgene.org/crispr/guide/ Here's some Crispr for plant experiments for about $400 https://www.addgene.org/kits/stuttmann-dicot-genome-editing/ https://www.addgene.org/kits/stuttmann-dicot-genome-editing/ So I'm sure there a lot more to it than that, but even so, it seems to me that the nuts and bolts of this stuff - once known - are going to be easy to produce. How long till we get a generic?
- Creationer 7y agoAt what point do you say: this child just isn't meant to be? Why would you subject someone to a life of annual spinal injections, and society to the huge financial cost?
- kinkrtyavimoodh 7y agoIn fact one could go a step further and argue that it's almost immoral to bring such a child to the world.
- Zarath 7y agoI don't think you're wrong but it is a very controversial topic
- inertiatic 7y agoAny reasonable individual would "subject themselves to a life of annual spinal injections" if the alternative was being dead. So, if the average person wouldn't tell themselves they're "just not meant to be", there is also no point where you get to say that for a child.
- Causality1 7y ago>The drug requires regular spinal infusions costing $750,000 in the first year and $375,000 annually thereafter, for life. I don't understand how this is justifiable. As an insurance company, the only way to cover this treatment is by raising premiums for all customers. By raising premiums, people on the edge of being able to afford insurance are pushed out. There is no way in hell this treatment doesn't cost more lives than it saves.
- TheOperator 7y agoWhich is why most insurance plans wouldn't cover it.
- negamax 7y agoReading at the comment and $8B acquisition cost and $1M profit. They just need to treat 8000 people. Eventually market forces will take over and cost will come down by magnitudes Hint: genome sequencing
- aaavl2821 7y agoAvexis, the company that Novartis acquired to get this drug, spent ~$700M developing it. The drug will treat a few hundred patients a year. Without a high price, it isn't profitable. for these drugs to get covered at such a high price, they have to be very effective, which this drug seems to be However, did Novartis have to charge $2M? Avexis was trading at a $3B market cap not long before Novartis bought it for $8.7B. Analysts were projecting a $1-1.25M price tag, which is closer to the cost effective range Novartis probably paid up for avexis bc it was a competitive deal process and they thought they could get away with a higher drug price than the market expected. At the time of the acquisition people thought Novartis was paying a premium for the platform, by charging $2M for the drug it seems like more of a pricing play than platform deal I wrote a case study on avexis with more detail here: https://www.baybridgebio.com/blog/most_expensive_drug.html https://www.baybridgebio.com/blog/most_expensive_drug.html
- JamesBarney 7y agoI've always been curious how that 700M breaks up? How much of that is FDA trials and how much is paying 1000 phds to work on designing drugs for 7 years. Of course the follow up question is there any way to get that number lower.
- aaavl2821 7y agoIt seems very high to me as well, especially since they were allowed to submit for approval with only one 15-patient study completed and interim data from a few other studies. I think they have tested the drug in under 100 pts to date Per the financial statements, ~$500M of that $700M was r&d (the rest was general and administrative expense). A lot of the r&d spend was payments to third party research and manufacturing firms. Given the small clinical trial size I'd imagine more money went to contract manufacturing than research. There are very few companies and people that can make gene therapies at scale at acceptable quality levels. It seems like this expertise is quite expensive. There was probably a lot of process development here since making these drugs at scale is so new (here "at scale" means "enough for ~100 patients") They also spent a lot building out their own manufacturing site. They also had a $135M license payment, I think to the company they licensed their viral vector from
- JamesAdir 7y agoI can't shake the feeling that the medical companies have huge incentives to develop drugs that are taken for a long period of time instead of one time treatment. There should be some government incentives that will make sure that companies who offer simple cheaper solutions will have some benefits out of it.